

INFINITY PHARMACEUTICALS, INC.

Form SC 13G

February 14, 2007

OMB APPROVAL  
OMB Number: 3235-0145  
Expires: February 28, 2009  
Estimated average burden  
hours per response...10.4

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**SCHEDULE 13G**

**Under the Securities Exchange Act of 1934  
(Amendment No. \_\_\_\_\_)\***

INFINITY PHARMACEUTICALS, INC.

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

254675101

(CUSIP Number)

December 31, 2006

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

CUSIP No. 254675101

Page 2 of 8

NAMES OF REPORTING PERSONS:

1

Venrock Associates

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

I.R.S. #13-6300995

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

2

(a)  p<sup>1</sup>

(b)  o

SEC USE ONLY:

3

CITIZENSHIP OR PLACE OF ORGANIZATION:

4

New York, United States

SOLE VOTING POWER:

5

NUMBER OF 0

SHARED VOTING POWER:

SHARES BENEFICIALLY OWNED BY 6

1,176,284<sup>2</sup>

SOLE DISPOSITIVE POWER:

EACH REPORTING PERSON 7

0

SHARED DISPOSITIVE POWER:

WITH: 8

1,176,284<sup>2</sup>

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

9

1,176,284<sup>2</sup>

**10** CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

o

**11** PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

6.0%<sup>3</sup>

**12** TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

PN

<sup>1</sup> Venrock Associates, Venrock Associates III, L.P. and Venrock Entrepreneurs Fund III, L.P. are members of a group for purposes of this Schedule 13G.

<sup>2</sup> Consists of 211,504 shares of common stock owned by Venrock Associates, 941,249 shares of common stock owned by Venrock Associates III, L.P. and 23,531 shares of common stock owned by Venrock Entrepreneurs Fund III, L.P.

<sup>3</sup> This percentage is calculated based upon 19,471,694 shares of the Issuer's common stock outstanding as of September 30, 2006, as set forth in the Issuer's most recent Form 10-Q for the quarter ended September 30, 2006, filed with the Securities and Exchange Commission on November 9, 2006.

---

CUSIP No. 254675101

Page 3 of 8

NAMES OF REPORTING PERSONS:

1

Venrock Associates III, L.P.

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

I.R.S. #13-4120290

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

2

(a)  p<sup>1</sup>

(b)  o

SEC USE ONLY:

3

CITIZENSHIP OR PLACE OF ORGANIZATION:

4

New York, United States

SOLE VOTING POWER:

5

NUMBER OF 0

SHARED VOTING POWER:

SHARES BENEFICIALLY OWNED BY 6

1,176,284<sup>2</sup>

SOLE DISPOSITIVE POWER:

EACH REPORTING PERSON 7

0

SHARED DISPOSITIVE POWER:

WITH: 8

1,176,284<sup>2</sup>

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

9

1,176,284<sup>2</sup>

**10** CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

o

**11** PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

6.0%<sup>3</sup>

**12** TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

PN

<sup>1</sup> Venrock Associates, Venrock Associates III, L.P. and Venrock Entrepreneurs Fund III, L.P. are members of a group for purposes of this Schedule 13G.

<sup>2</sup> Consists of 211,504 shares of common stock owned by Venrock Associates, 941,249 shares of common stock owned by Venrock Associates III, L.P. and 23,531 shares of common stock owned by Venrock Entrepreneurs Fund III, L.P.

<sup>3</sup> This percentage is calculated based upon 19,471,694 shares of the Issuer's common stock outstanding as of September 30, 2006, as set forth in the Issuer's most recent Form 10-Q for the quarter ended September 30, 2006, filed with the Securities and Exchange Commission on November 9, 2006.

---

CUSIP No. 254675101

Page 4 of 8

NAMES OF REPORTING PERSONS:

1

Venrock Entrepreneurs Fund III, L.P.

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

I.R.S. #13-4161054

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

2

(a)  p<sup>1</sup>

(b)  o

SEC USE ONLY:

3

CITIZENSHIP OR PLACE OF ORGANIZATION:

4

New York, United States

SOLE VOTING POWER:

5

NUMBER OF 0

SHARED VOTING POWER:

SHARES BENEFICIALLY OWNED BY 6

1,176,284<sup>2</sup>

SOLE DISPOSITIVE POWER:

EACH REPORTING PERSON 7

0

SHARED DISPOSITIVE POWER:

WITH: 8

1,176,284<sup>2</sup>

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

9

1,176,284<sup>2</sup>

**10** CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

o

**11** PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

6.0%<sup>3</sup>

**12** TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

PN

<sup>1</sup> Venrock Associates, Venrock Associates III, L.P. and Venrock Entrepreneurs Fund III, L.P. are members of a group for purposes of this Schedule 13G.

<sup>2</sup> Consists of 211,504 shares of common stock owned by Venrock Associates, 941,249 shares of common stock owned by Venrock Associates III, L.P. and 23,531 shares of common stock owned by Venrock Entrepreneurs Fund III, L.P.

<sup>3</sup> This percentage is calculated based upon 19,471,694 shares of the Issuer's common stock outstanding as of September 30, 2006, as set forth in the Issuer's most recent Form 10-Q for the quarter ended September 30, 2006, filed with the Securities and Exchange Commission on November 9, 2006.

---



CUSIP No. 254675101

Page 5 of 8

Introductory Note: This Statement on Schedule 13G is filed on behalf of Venrock Associates, a limited partnership organized under the laws of the State of New York ( Venrock ), Venrock Associates III, L.P., a limited partnership organized under the laws of the State of New York ( Venrock III ) and Venrock Entrepreneurs Fund III, L.P., a limited partnership organized under the laws of the State of New York ( Entrepreneurs Fund III ) and collectively with Venrock and Venrock III, the Venrock Entities ) in respect of shares of common stock of Infinity Pharmaceuticals, Inc.

**Item 1 (a) Name of Issuer:**

Infinity Pharmaceuticals, Inc.

**Item 1(b) Address of Issuer's Principal Executive Offices:**

780 Memorial Drive  
Cambridge, MA 02139

**Item 2(a) Name of Person Filing:**

Venrock Associates  
Venrock Associates III, L.P.  
Venrock Entrepreneurs Fund III, L.P.

**Item 2(b) Address of Principal Business Office or, if none, Residence:**

New York Office:  
30 Rockefeller Plaza  
Suite 5508  
New York, NY 10112

Menlo Park Office:  
2494 Sand Hill Road  
Suite 200  
Menlo Park, CA 94025

Cambridge Office:  
55 Cambridge Parkway  
Suite 100  
Cambridge, MA 02142

**Item 2(c) Citizenship:**

Each of Venrock, Venrock III and Entrepreneurs Fund III are limited partnerships organized in the State of New York.

**Item 2(d) Title of Class of Securities:**

Common Stock

**Item 2(e) CUSIP Number**

254675101

**Item 3** Not applicable.

**Item 4 Ownership**

(a) and (b) Venrock beneficially owns 211,504 shares of common stock, or 1.1% or the outstanding shares of common stock. Venrock III owns 941,249 shares of common

CUSIP No. 254675101

Page 6 of 8

stock, or 4.8% or the outstanding shares of common stock. Entrepreneurs Fund III owns 23,531 shares of common stock, or 0.1% or the outstanding shares of common stock.

(c) Each of the Venrock Entities has sole power to vote or to direct the vote of no shares of common stock, sole power to dispose or to direct the disposition of no shares of the common stock, shared power to vote or to direct the vote of 1,176,284 shares of the common stock and shared power to dispose or to direct the disposition of 1,176,284 shares of the common stock.

**Item 5 Ownership of Five Percent or Less of a Class:** If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o

**Item 6 Ownership of More than Five Percent on Behalf of Another Person:**

Not applicable.

**Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:**

Not applicable.

**Item 8 Identification and Classification of Members of the Group:**

This Schedule is being filed pursuant to Rule 13d-1(d). The identities of each of the Venrock Entities are stated in Item 2(a).

**Item 9 Notice of Dissolution of Group:**

Not applicable.

**Item 10 Certification**

Not applicable.

---

CUSIP No. 254675101

Page 7 of 8

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

Dated: February 14, 2007

VENROCK ASSOCIATES

By: /s/ Linda H. Hanauer  
Name: Linda H. Hanauer  
Title: Authorized Signatory or Member

Dated: February 14, 2007

VENROCK ASSOCIATES III, L.P.

By: /s/ Linda H. Hanauer  
Name: Linda H. Hanauer  
Title: Authorized Signatory or Member

Dated: February 14, 2007

VENROCK ENTREPRENEURS FUND III, L.P.

By: /s/ Linda H. Hanauer  
Name: Linda H. Hanauer  
Title: Authorized Signatory or Member

---

CUSIP No. 254675101

Page 8 of 8

**EXHIBIT INDEX**

Exhibit No.

99.1 Agreement pursuant to 13d-1(k)(1) among Venrock Associates, Venrock Associates III, L.P. and Venrock Entrepreneurs Fund III, L.P.